Sartorius and TheWell Bioscience Team up To Develop Hydrogels & Bioinks

Sartorius, a laboratory equipment supplier and TheWell Bioscience have agreed to collaborate on further improving hydrogels and bioinks custom-fitted to create 3D high-level cell models for drug discovery work processes. The firm will widen the portfolio of its lab division by disseminating TheWell Bioscience's items and putting resources into a minority shareholding in the organization.  

TheWell Bioscience is a trailblazer in the field of animal-free hydrogels and bioinks, which are the basic parts for the making of 3D biomimicking stages, otherwise called 3D cell models, for accurate medication, cell treatment and biomanufacturing.

"Sartorius’ lab division is fully focused on helping researchers speed up the development of new drugs with innovative technologies. The offering of TheWell Bioscience seamlessly complements our bioanalytic instruments, cytokines and media products used to grow and analyze a range of 3D spheroid and organoid models. Their hydrogel solutions are highly compatible with our live-cell imaging system for monitoring and analyzing cell health and behaviour in real time. By collaborating, we will enable customers to get more relevant insights in less time, accelerating time to market," said Fiona Coats, head of marketing at Sartorius’ Lab Products & Services division, who will join the board of directors of TheWell Bioscience as part of the collaboration.

"Our portfolio today encompasses 60 synthetic, room-temperature-stable animal-free hydrogels, bioinks, solutions, and functional assays for biopharma customers to move away from animal-based extracellular matrices for 3D cell models and injectable delivery. The collaboration with Sartorius will broaden our reach in the life science and biopharma market and enable more customers to speed up their research in advanced biomedicine and personalized therapies," said John Huang, founder and CEO of TheWell Bioscience.